| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 727,200 | 844,600 | 1,460,000 | 1,391,600 |
| Depreciation and amortization | 123,200 | 145,000 | 136,700 | 135,100 |
| Stock-based compensation expense | 257,400 | 249,300 | 237,000 | 251,700 |
| Gains on marketable and other securities, net | 25,000 | -21,500 | 577,700 | 250,000 |
| Other, net | -55,600 | -136,900 | -16,300 | 20,900 |
| Deferred income taxes | 96,000 | 232,500 | 278,600 | 135,200 |
| Decrease in accounts receivable | -1,200 | 51,200 | 80,300 | 28,200 |
| Decrease (increase) in inventories | -26,600 | -2,100 | 82,600 | 42,500 |
| Increase in prepaid expenses and other assets | 198,600 | -82,800 | 47,900 | 230,700 |
| Increase in deferred revenue | 99,600 | -3,100 | 76,600 | -142,900 |
| Increase (decrease) in accounts payable, accrued expenses, and other liabilities | 107,700 | -24,700 | 759,200 | 216,400 |
| Total adjustments | 351,700 | 326,100 | 158,700 | -247,200 |
| Net cash provided by operating activities | 1,078,900 | 1,170,700 | 1,618,700 | 1,144,400 |
| Purchases of marketable and other securities | 2,755,900 | 2,043,700 | 3,520,200 | 2,855,100 |
| Sales or maturities of marketable and other securities | 2,606,500 | 2,555,000 | 3,365,000 | 2,167,900 |
| Capital expenditures | 230,600 | 248,700 | 201,400 | 219,000 |
| Proceeds from sale of property, plant, and equipment | NaN | 0 | 0 | 0 |
| Payments for intangible assets | 48,900 | 42,000 | 43,300 | 187,800 |
| Acquisitions, net of cash acquired | NaN | 300 | 3,000 | 0 |
| Net cash (used in) provided by investing activities | -428,900 | 220,300 | -402,900 | -1,094,000 |
| Proceeds from issuance of common stock | 163,100 | 503,500 | 40,300 | 31,500 |
| Payments in connection with common stock tendered for employee tax obligations | 73,200 | 519,200 | 3,000 | 5,600 |
| Repurchases of common stock | 794,300 | 671,700 | 664,000 | 1,061,500 |
| Dividends paid | 97,800 | 92,700 | 91,200 | 92,600 |
| Other | 0 | 0 | 0 | 0 |
| Net cash used in financing activities | -802,200 | -780,100 | -717,900 | -1,128,200 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | -900 | -300 | -400 | 400 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -153,100 | 610,600 | 497,500 | -1,077,400 |
| Cash, cash equivalents, and restricted cash at beginning of period | 3,123,700 | 2,513,100 | 2,015,600 | 3,093,000 |
| Cash, cash equivalents, and restricted cash at end of period | 2,970,600 | 3,123,700 | 2,513,100 | 2,015,600 |
REGENERON PHARMACEUTICALS, INC. (REGN)
REGENERON PHARMACEUTICALS, INC. (REGN)